A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial.
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D007267:Injections; D008297:Male; D008875:Middle Aged; D010169:Palmitic Acids / Q000627:therapeutic use; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010169:Palmitic Acids; D010880:Piperidines; D013449:Sulfonamides; D007099:Imipramine; D003975:Diazepam; D005476:Fluphenazine